International prescribing patterns for mood illness: The international mood network (IMN)

Mauer, Sivan; Alahmari, Rami; Vöhringer, Paul A.; Vergne, Derick; Lövdahl, H.; Correa, EI; Patkar, Ashwin A.; Pae, Chi‐Un; Strejilevich, Sergio; Dalley, Shannon; Ghaemi, S. Nassir

doi:10.1016/j.jad.2014.05.049

Cited by 15 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, anticonvulsants were present at any level in 21% of BD suicide deaths, most commonly being carbamazepine (14%), with the other anticonvulsants below the privacy threshold. The high number of deaths in which carbamazepine was present was an unexpected finding, especially given the declining use in clinical practice for BD, which is currently estimated at 3% of BD patients (Mauer et al 2014 ). There is a modest literature suggesting higher rates of suicide attempts during treatment with carbamazepine monotherapy compared to lithium monotherapy (Cipriani et al 2013 ; Goodwin et al 2003 ), but other factors such as relative toxicity in overdose (Spiller et al 1990 ) and profile of patients who are prescribed carbamazepine (Leon et al 2012 ) may also be at play.…”

Section: Discussionmentioning

confidence: 99%

Self-poisoning suicide deaths in people with bipolar disorder: characterizing a subgroup and identifying treatment patterns

Schaffer

Weinstock

Sinyor

et al. 2017

Int J Bipolar Disord

View full text Add to dashboard Cite

ObjectiveTo characterize self-poisoning suicide deaths in BD compared to other suicide decedents.MethodsExtracted coroner data from all suicide deaths (n = 3319) in Toronto, Canada from 1998 to 2012. Analyses of demographics, clinical history, recent stressors, and suicide details were conducted in 5 subgroups of suicide decedents: BD self-poisoning, BD other methods, non-BD self-poisoning, non-BD other methods, and unipolar depression self-poisoning. Toxicology results for lethal and present substances were also compared between BD and non-BD self-poisoning subgroups as well as between BD and unipolar depression self-poisoning subgroups.ResultsAmong BD suicide decedents, self-poisoning was significantly associated with female sex, past suicide attempts, and comorbid substance abuse. In both the BD and non-BD self-poisoning groups, opioids were the most common class of lethal medication. For both groups, benzodiazepines and antidepressants were the most common medications present at time of death, and in 23% of the BD group, an antidepressant was present without a mood stabilizer or antipsychotic. Only 31% of the BD group had any mood stabilizer present, with carbamazepine being most common. No antidepressant, mood stabilizer, or antipsychotic was present in 15.5% of the BD group. Relative to unipolar depression self-poisoning group, the BD self-poisoning group evidenced higher proportion of previous suicide attempt(s) and psychiatry/ER visits in the previous week.ConclusionPeople with BD who die by suicide via self-poisoning comprise a distinct but understudied group. The predominant absence of guideline-concordant pharmacologic care comprises a crucial target for future policy and knowledge translation efforts.

show abstract

Section: Discussionmentioning

confidence: 99%

Self-poisoning suicide deaths in people with bipolar disorder: characterizing a subgroup and identifying treatment patterns

Schaffer

Weinstock

Sinyor

et al. 2017

Int J Bipolar Disord

View full text Add to dashboard Cite

show abstract

“…However, negligence of BAEs is especially impressive in the case of the use of APs in BDs patients. Although an increasing number of people affected by these disorders are being treated with these kinds of drugs (Pillarella et al 2012 ; Mauer et al 2014 ), the lessons learned from schizophrenia about antipsychotic-related BAEs do not seem to have influenced this clinical field. As shown in this review, there are no studies exploring the subjective and behavioral impact of these drugs and their possible therapeutic and functional consequences on patients with BDs.…”

Section: Discussionmentioning

confidence: 99%

Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications

Szmulewicz

Samamé

Caravotta

et al. 2016

Int J Bipolar Disord

View full text Add to dashboard Cite

BackgroundBehavioral and emotional adverse events induced by drugs commonly prescribed to patients with bipolar disorders are of paramount importance to clinical practice and research. However, no reviews on the topic have been published so far.MethodsAn extensive search was performed. Reports were reviewed if they described behavioral side effects related to pharmacological treatments for bipolar disorders in healthy subjects or patients with different neuropsychiatric disorders. For this review, lithium, antipsychotics, anticonvulsants and selective serotonin reuptake inhibitors were included.ResultsApathy or emotional blunting, diminished sexual desire, and inability to cry were reported to be associated with exposure to selective serotonin reuptake inhibitors. Neuroleptic-induced deficit syndrome/emotional detachment and obsessive–compulsive symptomatology and decision-making modifications. A lithium-related amotivational syndrome was also reported in the literature. Furthermore, hypersexuality and obsessive–compulsive symptoms have been noted in subjects treated with lamotrigine.LimitationsPrimary studies on drug-related adverse events are scant so far and most of the data currently available derive from case reports. Moreover, most of the evidence reviewed is based on studies performed on healthy subjects and patients with neuropsychiatric conditions other than bipolar disorders.DiscussionThere is a remarkable dearth of data on behavioral adverse events of pharmacological treatment for bipolar disorders. However, the pieces of evidence available at present, though scant and scattered, suggest that different behavioral adverse events may be related to pharmacological treatment for these disorders. The implications of these findings for research and management of patients with mood disorders are discussed.

show abstract

“…The use of antidepressant medications is a controversial issue and perhaps more so in BD II because depressive features are so much more prominent. However, expert opinion recommends caution in their use (Mauer et al, 2014; Pacchiarotti et al, 2013a). The risks of rapid cycling, mixed states and switching into mania, are potential consequences, and efficacy is sometimes disappointing.…”

Section: Clinical Management Of Mood Disorders With Complex Presentatmentioning

confidence: 99%

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

Malhi

Bassett

Boyce

et al. 2015

Aust N Z J Psychiatry

672

681

View full text Add to dashboard Cite

Professor Marie-Paule Austin, Professor Michael Berk, Dr Yulisha Byrow, Professor Helen Christensen, Dr Nick De Felice, A/Professor Seetal Dodd, A/Professor Megan Galbally, Dr Josh Geffen, Professor Philip Hazell, A/Professor David Horgan, A/Professor Felice Jacka, Professor Gordon Johnson, Professor Anthony Jorm, Dr Jon-Paul Khoo, Professor Jayashri Kulkarni, Dr Cameron Lacey, Dr Noeline Latt, Professor Florence Levy, A/Professor Andrew Lewis, Professor Colleen Loo, Dr Thomas Mayze, Dr Linton Meagher, Professor Philip Mitchell, Professor Daniel O'Connor, Dr Nick O'Connor, Dr Tim Outhred, Dr Mark Rowe, Dr Narelle Shadbolt, Dr Martien Snellen, Professor John Tiller, Dr Bill Watkins, Dr Raymond Wu.

show abstract

International prescribing patterns for mood illness: The international mood network (IMN)

Cited by 15 publications

References 18 publications

Self-poisoning suicide deaths in people with bipolar disorder: characterizing a subgroup and identifying treatment patterns

Self-poisoning suicide deaths in people with bipolar disorder: characterizing a subgroup and identifying treatment patterns

Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

Contact Info

Product

Resources

About